Consortium wins £1m grant to develop in the field test for Ebola

Published: 26-Mar-2015
Research & Development Infection Control

Public Health England (PHE) scientists will head the group researching the test


Public Health England (PHE) scientists are heading a consortium researching a rapid ‘in the field' Ebola test, following the successful award of funding from the Innovative Medicines Initiative (IMI).

The IMI, through its Ebola+ programme, will fund PHE with a £1m grant to coordinate a consortium, called MOFÍNA, of European public and private sector scientists to develop and validate a new test for Ebola, which it is hoped will enable medical workers to diagnose patients on site.

The research team aims to develop and validate a molecular point of care (POC) system suitable for safe, specific and sensitive detection of Ebola virus infection in the field. The system is based on the existing CE-marked assay marketed by altona Diagnostics of Hamburg, Germany and an integrated molecular diagnostic platform from Alere Inc headquartered in Waltham, MA. This molecular point of care system will detect the genetic material of Ebola viruses at a sensitivity and specificity comparable with test systems performed at central laboratories.

Professor Miles Carroll, Head of Research, Microbiology Services for PHE, said: 'If our research is successful, it could be possible to diagnose a suspected case on site in 30–40 minutes, which will dramatically decrease mortality rates.

Patients will be treated faster leading to a greater chance of their survival

'Patients will be treated faster leading to a greater chance of their survival. It will also help medical staff stop the spread of infection and ultimately bring outbreaks to an end.'

Chief Medical Officer Dame Sally Davies said: 'A rapid diagnostic test has the potential to reduce the devastating effects of Ebola that have affected West Africa during the recent outbreak. This is a fantastic opportunity for Public Health England to significantly improve how we treat Ebola patients and ultimately stop the spread of the virus.'

Dr Seshadri Vasan, PHE's business lead for the project, said: 'There is a need for rapid, accurate Ebola tests that can be used on site. We're aiming to develop a test that can be administered safely and used in locations where laboratories are unavailable.

'Our Public Health England scientists are on the front lines in West Africa, working with academic and private sector partners from around the world to develop therapeutic and diagnostic options for Ebola.'

  • Companies:
  • Public Health England
See more

You may also like

Media

Needle-free vaccine collaboration for emergent threat pathogens

Read more
Enesi Pharma has entered a research and development collaboration with Public Health England

Trending Articles

  1. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  2. Thermo Fisher Scientific officially opens US oral solid dose testing and R&D facility The company's further expansion in the Bend, Oregon area will assist its pharmaceutical clients in the early development of oral solid dosage (OSD) forms
  3. BioMarin Pharmaceutical expands Cork targeted therapy manufacturing facility with new lab The Irish facility is responsible for the development and commercialisation of therapies that address genetic conditions, and this expansion will allow the company to enhance its approved medicine production capacity
  4. Medac and chiron develop organ-on chip tech for animal free drug testing The companies aim to develop an animal-free pharmaceutical testing method that utilises organ-on chip technology, and will be used in rheumatoid arthritis drug testing
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Parenteral preparations: formulation challenges Parenteral preparations are defined as solutions, suspensions, emulsions for injection or infusion, powders for injection or infusion, gels for injection and implants. They are sterile preparations that are administrated directly into the systemic circulation of humans or animals

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Media

Needle-free vaccine collaboration for emergent threat pathogens

Enesi Pharma has entered a research and development collaboration with Public Health England
Infection Control

Three new labs staffed by PHE identify new Ebola cases in Sierra Leone

New labs are now fully operational in Sierra Leone, adding much needed capacity in critical districts and relieving the bottleneck in testing
Research & Development

Kymab and the Wellcome Trust initiate Ebola project

Drug discovery partnership to produce an antibody based medicine to fight Ebola infection
Infection Control

Bioquell and Public Health England support fight against CPE superbug in UK

In response to the superbug red alert warning raised by Public Health England, a UK firm has detailed a range of support measures that are effective against CPE
Research & Development

Public Health England and NanoViricides sign testing agreement

Agreement concerns testing of various nanoviricides against specific viruses of current concern
Research & Development

Opinion: Staring into the abyss

The price to overcome the problem of antibiotic resistance will be high
Infection Control

HPA and 2,147 children set a new Guinness World Record

Stages world\'s largest simultaneous hand hygiene lesson at multiple venues
Subscribe now